Dec 31, 2025 • GuruFocus
NEUTRAL
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)
Andrew Callos, Executive Vice President and Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 1,809 shares of the company on December 29, 2025. This transaction adds to his previous sales, with a total of 125,885 shares sold over the past year and no purchases. The stock's current valuation suggests it might be a "Possible Value Trap" according to its GF Value.
Dec 30, 2025 • MarketBeat
NEUTRAL
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock
Cytokinetics EVP Andrew Callos sold 1,809 shares of CYTK stock on December 29th for approximately $112,954, reducing his holdings by 3.4%. This follows other substantial sales by Callos earlier in December. Despite this insider selling, analysts maintain a "Moderate Buy" rating for Cytokinetics with an average target price of $83.61.
Dec 29, 2025 • DC News Now
BEARISH
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated (NASDAQ:CYTK) securities. The firm encourages shareholders who bought shares before December 27, 2023, and still hold them, to inquire about a securities investigation concerning potential corporate wrongdoing by Cytokinetics and its officers/directors. Investors can assist the investigation by visiting the firm's website or contacting them directly.
Dec 28, 2025 • KXAN Austin
BEARISH
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders who purchased securities before December 27, 2023, and still hold them. The investigation concerns potential corporate wrongdoing by Cytokinetics' officers and/or directors. Shareholders are encouraged to contact the firm for more information and to assist in the investigation.
Dec 26, 2025 • WDHN
BEARISH
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Cytokinetics, Incorporated (NASDAQ:CYTK) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased CYTK securities before December 27, 2023, and still hold them, to connect and assist the investigation. The investigation aims to determine if the company and its officers engaged in misconduct.
Dec 25, 2025 • WREG.com
BEARISH
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (CYTK) for alleged corporate wrongdoing. The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to connect to assist in the investigation. The investigation aims to determine if the company or its officers/directors engaged in corporate misconduct.